Vistagen Therapeutics

VTGN on Nasdaq. Market value $7m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Look carefully before going further

Why it could be worth it

Nothing stands out yet.

Read the warning sign in its own filings

This is not advice.

Compare with another stock

Who owns it

None of the long-term investors we follow own it. 49 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

7 investors own more than 5%.

  • Janus Henderson Biotech Innovation Master Fund Ltd
    Passive investor
    11.7%
    Since 29 August 2025
  • TCG Crossover GP II, LLC
    Passive investor
    at least 7.6%
    (filed with 1 related holder)
    Since 31 March 2026
  • Chen Yu
    Passive investor
    at least 6.7%−3.3 pts
    (filed with 4 related holders)
    Since 30 June 2026
  • at least 5.0%−1.3 pts
    (filed with 2 related holders)
    Since 31 December 2025
  • at least 4.7%−5.3 pts
    (filed with 2 related holders)
    Since 31 December 2025
  • BVF PARTNERS L P/IL
    Passive investor
    at least 3.7%−6.3 pts
    (filed with 9 related holders)
    Since 30 September 2026
  • Commodore Capital LP
    Passive investor
    at least 3.7%−6.2 pts
    (filed with 3 related holders)
    Since 30 September 2026
  • The Vanguard Group
    Passive investor
    Sold down below 5%
    Since 31 December 2025
  • StemPoint Capital LP
    Passive investor
    Sold down below 5%
    Since 31 December 2025
  • ORBIMED ADVISORS LLC
    Passive investor
    Sold down below 5%
    Since 30 June 2026
  • Sold down below 5%
    Since 31 December 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought or sold on the open market in the last 12 months.

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Vistagen Therapeutics’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 15 Jun 2026, plus the 10-Q filed 13 Nov 2026 and 14 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “As of November 13, 2026, the issuance date of the condensed consolidated financial statements as of and for the three and six months ended September 30, 2026 in this Report, there is uncertainty about whether the Company's combined cash, cash equivalents, and marketable securities will be sufficient to fund operations beyond twelve months from the issuance date of these condensed consolidated financial statements and therefore the Company concluded that substantial doubt exists about its ability to continue as a going concern.”
    Show the full paragraph
    As of September 30, 2026, the Company had cash, cash equivalents, and marketable securities of $ 20.0 million. As of November 13, 2026, the issuance date of the condensed consolidated financial statements as of and for the three and six months ended September 30, 2026 in this Report, there is uncertainty about whether the Company's combined cash, cash equivalents, and marketable securities will be sufficient to fund operations beyond twelve months from the issuance date of these condensed consolidated financial statements and therefore the Company concluded that substantial doubt exists about its ability to continue as a going concern.

    From the 10-Q filed 13 November 2026, Part I, Item 1. Financial Statements. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.